GlassScriptPhysician profile
Vincent P Tran
NPI 1245284074
$5,715.71
in general payments reported to CMS, 2019-2025
36 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $1,117 · 2021: $1,063 · 2022: $781 · 2023: $705 · 2024: $867 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $980.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $764.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.33 | 2019-2025 | Jardiance |
| Abbvie INC. | $526.04 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $347.15 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Allergan, INC. | $174.23 | 2020 | |
| Lilly USA, LLC | $163.95 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $161.41 | 2022-2025 | |
| Pfizer INC. | $157.08 | 2020-2025 | |
| Exact Sciences Corporation | $106.03 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $79.35 | 2023-2024 | Quviviq |
| Emd Serono, INC. | $72.70 | 2019 | |
| Genentech USA, INC. | $70.66 | 2019-2021 | |
| Abbott Laboratories | $65.95 | 2023-2024 | Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.23 | 2023-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $56.27 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $41.05 | 2024 | Opsumit |
| Depuy Synthes Sales INC. | $36.01 | 2019-2023 | Orthovisc |
| Teva Pharmaceuticals USA, INC. | $29.54 | 2022 | |
| Horizon Therapeutics Plc | $23.73 | 2022 | |
| Axsome Therapeutics, INC. | $18.80 | 2025 | Auvelity |
| Protega Pharmaceutials INC | $17.00 | 2023 | Roxybond |
| Amgen INC. | $15.85 | 2023 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $15.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.52 | 2024 | Zoryve |
| Daiichi Sankyo INC. | $14.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.89 | 2021 | |
| Eisai INC. | $13.94 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.73 | 2021 | |
| Nevro Corp. | $13.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.61 | 2019 | |
| Almatica Pharma LLC | $13.05 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.73 | 2022 | |
| Phadia US INC. | $12.42 | 2022 | |
| Sanofi Pasteur INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.